Contact

All Stories

  1. Validation of an AI‐Assisted Framework for Systematic Bias Assessment in Observational Studies

    Article • Journal of Evaluation in Clinical Practice, September 2026, Wiley

    Dr. Antonios Douros

  2. UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic...

    Article • Clinical Pharmacology & Therapeutics, August 2026, Wiley

    Dr. Antonios Douros

  3. Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation

    Article • JAMA Network Open, May 2026, American Medical Association (AMA)

    Dr. Antonios Douros

  4. Validation of an AI-Assisted Framework for Systematic Bias Assessment in Observational Studies

    Article • April 2026, openRxiv

    Dr. Antonios Douros

  5. Re‐evaluation of sucralose (E 955) as a food additive and evaluation of a new application on extension of use of sucralose (E 955) in fine bakery wares

    Article • EFSA Journal, February 2026, Wiley

    Dr. Antonios Douros

  6. Influenza Immunization at Midlife and the Risk of Parkinson Disease

    Article • JAMA Network Open, December 2025, American Medical Association (AMA)

    Dr. Antonios Douros

  7. Use of fluoroquinolones and the risk of seizures: a population-based cohort study

    Article • Clinical Microbiology and Infection, December 2025, Elsevier

    Dr. Antonios Douros

  8. Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

    Article • British Journal of Clinical Pharmacology, November 2025, Wiley

    Dr. Antonios Douros

  9. A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis

    Article • Scientific Reports, November 2025, Springer Science + Business Media

    Dr. Antonios Douros

  10. Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

    Article • Diabetes Obesity and Metabolism, November 2025, Wiley

    Dr. Antonios Douros

  11. Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study

    Article • BMC Medicine, October 2025, Springer Science + Business Media

    Dr. Antonios Douros

  12. Serum uric acid and the risk of major adverse cardiovascular events and death among older adults: a population-based prospective cohort study

    Article • BMC Geriatrics, October 2025, Springer Science + Business Media

    Dr. Antonios Douros

  13. Invited Commentary: Building rigorous clinical evidence for drug-drug interactions

    Article • American Journal of Epidemiology, October 2025, Oxford University Press (OUP)

    Dr. Antonios Douros

  14. Ibuprofen gegen alles?

    Article • Die Orthopädie, August 2025, Springer Science + Business Media

    Dr. Antonios Douros

  15. Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies

    Article • European Journal of Clinical Pharmacology, July 2025, Springer Science + Business Media

    Dr. Antonios Douros

  16. The Risk of Bleeding in Pregnant Women with Acute Venous Thromboembolism Treated with Anticoagulants: An International Multi-Database Cohort Study

    Article • Journal of Thrombosis and Haemostasis, July 2025, Elsevier

    Dr. Antonios Douros

  17. Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research

    Article • Pharmacoepidemiology and Drug Safety, July 2025, Wiley

    Dr. Antonios Douros

  18. CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence

    Article • Hypertension, June 2025, Wolters Kluwer Health

    Dr. Antonios Douros

  19. Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2025, Taylor & Francis

    Dr. Antonios Douros

  20. Evaluation of Drug–Drug Interactions in Pharmacoepidemiologic Research

    Article • Pharmacoepidemiology and Drug Safety, January 2025, Wiley

    Dr. Antonios Douros

  21. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events

    Article • Pharmacoepidemiology and Drug Safety, January 2025, Wiley

    Dr. Antonios Douros

  22. Handbook of Epidemiology

    Article • January 2025, Springer Science + Business Media

    Dr. Antonios Douros

  23. The Prevalent New‐User Design to Study Drug–Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia

    Article • Pharmacoepidemiology and Drug Safety, October 2024, Wiley

    Dr. Antonios Douros

  24. Comparative risk of infection of medications used for type 2 diabetes

    Article • Expert Opinion on Drug Safety, September 2024, Taylor & Francis

    Dr. Antonios Douros

  25. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events

    Article • September 2024, Authorea, Inc.

    Dr. Antonios Douros

  26. Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta‐Analysis

    Article • Pharmacoepidemiology and Drug Safety, August 2024, Wiley

    Dr. Antonios Douros

  27. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis

    Article • Drug Safety, May 2024, Springer Science + Business Media

    Dr. Antonios Douros

  28. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study

    Article • Diabetes Obesity and Metabolism, May 2024, Wiley

    Dr. Antonios Douros

  29. Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology

    Article • Current Epidemiology Reports, March 2024, Springer Science + Business Media

    Dr. Antonios Douros

  30. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study

    Article • Thrombosis Research, March 2024, Elsevier

    Dr. Antonios Douros

  31. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study

    Article • February 2024, IOS Press

    Dr. Antonios Douros

  32. Diagnostic Validity of Chronic Kidney Disease in Health Claims Data Over Time: Results from a Cohort of Community-Dwelling Older Adults in Germany

    Article • Clinical Epidemiology, February 2024, Taylor & Francis

    Dr. Antonios Douros

  33. Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study

    Article • Alzheimer s & Dementia, December 2023, Wiley

    Dr. Antonios Douros

  34. Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies

    Article • Diabetes Obesity and Metabolism, November 2023, Wiley

    Dr. Antonios Douros

  35. Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation

    Article • Clinical Kidney Journal, September 2023, Oxford University Press (OUP)

    Dr. Antonios Douros

  36. Risk of opioid-related mortality associated with buprenorphine versus methadone: A systematic review of observational studies

    Article • August 2023, openRxiv

    Dr. Antonios Douros

  37. Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP‐4 inhibitors: population‐based cohort study

    Article • Clinical Pharmacology & Therapeutics, June 2023, Wiley

    Dr. Antonios Douros

  38. Kidney Measures and Risk of Incident Heart Failure Among Older Adults

    Article • JACC Heart Failure, June 2023, Elsevier

    Dr. Antonios Douros

  39. Considerations on the use of different comparators in pharmacovigilance: a methodological review

    Article • British Journal of Clinical Pharmacology, May 2023, Wiley

    Dr. Antonios Douros

  40. Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals with Hypertens...

    Article • American Journal of Epidemiology, April 2023, Oxford University Press (OUP)

    Dr. Antonios Douros

  41. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting ‐ A disproportionality analysis

    Article • British Journal of Clinical Pharmacology, March 2023, Wiley

    Dr. Antonios Douros

  42. Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population‐based cohort study

    Article • Diabetes Obesity and Metabolism, February 2023, Wiley

    Dr. Antonios Douros

  43. Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review

    Article • International Journal of Cardiovascular Sciences, January 2023, Sociedade Brasileira de Cardiologia

    Dr. Antonios Douros

  44. Common vaccines and the risk of incident dementia: a population-based cohort study

    Article • The Journal of Infectious Diseases, December 2022, Oxford University Press (OUP)

    Dr. Antonios Douros

  45. Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study

    Article • Diabetes Care, December 2022, American Diabetes Association

    Dr. Antonios Douros

  46. Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes

    Article • Frontiers in Pharmacology, November 2022, Frontiers

    Dr. Antonios Douros

  47. Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multi-database cohort study

    Article • The American Journal of Medicine, September 2022, Elsevier

    Dr. Antonios Douros

  48. Obesity as a modifier of the Cardiovascular effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes

    Article • Diabetes Research and Clinical Practice, September 2022, Elsevier

    Dr. Antonios Douros

  49. Concomitant Use of Sulfonylureas and Warfarin and the Risk of Severe Hypoglycemia: Population-Based Cohort Study

    Article • Diabetes Care, August 2022, American Diabetes Association

    Dr. Antonios Douros

  50. Bleeding in women with venous thromboembolism during pregnancy: A systematic review of the literature

    Article • Research and Practice in Thrombosis and Haemostasis, August 2022, Wiley

    Dr. Antonios Douros

  51. Response to: Real‐World Data on the Risk of Ventricular Arrhythmias with Sulfonamides

    Article • Clinical Pharmacology & Therapeutics, June 2022, Wiley

    Dr. Antonios Douros

  52. Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data

    Article • Current Drug Safety, May 2022, Bentham Science Publishers

    Dr. Antonios Douros

  53. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials

    Article • PLOS One, March 2022, PLOS

    Dr. Antonios Douros

  54. 5‐Alpha Reductase Inhibitors and the Risk of Anemia among Men with Benign Prostatic Hyperplasia: A Population‐based Cohort Study

    Article • British Journal of Clinical Pharmacology, March 2022, Wiley

    Dr. Antonios Douros

  55. Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies

    Article • Clinical Pharmacology & Therapeutics, March 2022, Wiley

    Dr. Antonios Douros

  56. Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi‐database cohort study

    Article • Research and Practice in Thrombosis and Haemostasis, January 2022, Wiley

    Dr. Antonios Douros

  57. Pharmacoepidemiology

    Article • January 2022, Springer Science + Business Media

    Dr. Antonios Douros

  58. Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom

    Article • American Journal of Hypertension, August 2021, Oxford University Press (OUP)

    Dr. Antonios Douros

  59. Utilization and long‐term persistence of direct oral anticoagulants among patients with non‐valvular atrial fibrillation and liver disease

    Article • British Journal of Clinical Pharmacology, August 2021, Wiley

    Dr. Antonios Douros

  60. Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study

    Article • BMC Health Services Research, July 2021, Springer Science + Business Media

    Dr. Antonios Douros

  61. The Modifying Effects of Adiposity on the Cardiovascular Safety of Sulfonylureas

    Article • Diabetes Obesity and Metabolism, July 2021, Wiley

    Dr. Antonios Douros

  62. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study

    Article • Journal of Alzheimer’s Disease, May 2021, IOS Press

    Dr. Antonios Douros, Paul Brassard

  63. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence

    Article • Expert Opinion on Drug Metabolism & Toxicology, April 2021, Taylor & Francis

    Dr. Antonios Douros

  64. Global COVID ‐19 Pandemic and Reporting Behavior ‐ An Analysis of the Food and Drug Administration Adverse Events Reporting System ( FAERS )

    Article • Pharmacoepidemiology and Drug Safety, March 2021, Wiley

    Dr. Antonios Douros

  65. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism

    Article • Thrombosis Research, March 2021, Elsevier

    Dr. Antonios Douros

  66. Domperidone and the Risks of Sudden Cardiac Death and Ventricular Arrhythmia: A Systematic Review and Meta‐Analysis of Observational Studies

    Article • British Journal of Clinical Pharmacology, January 2021, Wiley

    Dr. Antonios Douros

  67. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis

    Article • Pharmacology Research & Perspectives, January 2021, Wiley

    Dr. Antonios Douros

  68. Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study

    Article • Age and Ageing, December 2020, Oxford University Press (OUP)

    Dr. Antonios Douros

  69. Sodium-glucose co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: a cohort study

    Article • The American Journal of Medicine, December 2020, Elsevier

    Dr. Antonios Douros

  70. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

    Article • BMJ, September 2020, BMJ

    Dr. Antonios Douros

  71. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

    Article • Diabetes Care, August 2020, American Diabetes Association

    Dr. Antonios Douros

  72. Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study

    Article • Neurology, August 2020, Wolters Kluwer Health

    Dr. Antonios Douros

  73. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

    Article • Annals of Internal Medicine, July 2020, American College of Physicians

    Dr. Antonios Douros

  74. Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study

    Article • Diabetes Obesity and Metabolism, May 2020, Wiley

    Dr. Antonios Douros

  75. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis

    Article • European Journal of Clinical Pharmacology, May 2020, Springer Science + Business Media

    Dr. Antonios Douros

  76. Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study

    Article • BMC Geriatrics, January 2020, Springer Science + Business Media

    Dr. Antonios Douros

  77. Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population‐based cohort study

    Article • Diabetes Obesity and Metabolism, October 2019, Wiley

    Dr. Antonios Douros

  78. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk

    Article • Neurology, August 2019, Wolters Kluwer Health

    Dr. Antonios Douros

  79. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes

    Article • Diabetes Care, July 2019, American Diabetes Association

    Dr. Antonios Douros

  80. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Adverse Cardiovascular Events: A Population‐based Cohort Study

    Article • British Journal of Clinical Pharmacology, July 2019, Wiley

    Dr. Antonios Douros

  81. Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence

    Article • Expert Opinion on Drug Metabolism & Toxicology, June 2019, Taylor & Francis

    Dr. Antonios Douros, Siyana Kurteva

  82. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes

    Article • Diabetes Care, June 2019, American Diabetes Association

    Dr. Antonios Douros

  83. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies

    Article • Drug Safety, June 2019, Springer Science + Business Media

    Dr. Antonios Douros

  84. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer

    Article • Journal of Hypertension, May 2019, Wolters Kluwer Health

    Dr. Antonios Douros

  85. RE: Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication

    Article • JNCI Journal of the National Cancer Institute, April 2019, Oxford University Press (OUP)

    Dr. Antonios Douros

  86. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study

    Article • European Heart Journal, February 2019, Oxford University Press (OUP)

    Dr. Antonios Douros

  87. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®

    Article • Journal of General Internal Medicine, December 2018, Springer Science + Business Media

    Dr. Antonios Douros

  88. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study

    Article • BMJ, December 2018, BMJ

    Dr. Antonios Douros

  89. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

    Article • The American Journal of Medicine, October 2018, Elsevier

    Dr. Antonios Douros

  90. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy

    Article • Diabetes Care, August 2018, American Diabetes Association

    Dr. Antonios Douros

  91. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

    Article • BMJ, July 2018, BMJ

    Dr. Antonios Douros

  92. Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes

    Article • Epidemiology, July 2018, Wolters Kluwer Health

    Dr. Antonios Douros

  93. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

    Article • BMJ, March 2018, BMJ

    Dr. Antonios Douros

  94. Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review

    Article • CNS Drugs, March 2018, Springer Science + Business Media

    Dr. Antonios Douros

  95. Non–Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury

    Article • Journal of the American College of Cardiology, March 2018, Elsevier

    Dr. Antonios Douros

  96. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study

    Article • Current Vascular Pharmacology, January 2018, Bentham Science Publishers

    Dr. Antonios Douros

  97. Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study


    Article • Clinical Nephrology, January 2018, Dustri-Verlgag Dr. Karl Feistle

    Dr. Antonios Douros

  98. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study

    Article • Pharmacoepidemiology and Drug Safety, October 2017, Wiley

    Dr. Antonios Douros

  99. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

    Article • Diabetes Care, September 2017, American Diabetes Association

    Dr. Antonios Douros, Samy Suissa

  100. Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia

    Article • Pharmacoepidemiology and Drug Safety, May 2017, Wiley

    Dr. Antonios Douros

  101. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System

    Article • Journal of Clinical Pharmacy and Therapeutics, September 2016, Wiley

    Dr. Antonios Douros

  102. Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions

    Article • British Journal of Clinical Pharmacology, June 2016, Wiley

    Dr. Antonios Douros, Tania Schink

  103. Pharmakovigilanz in Deutschland

    Article • Der Internist, May 2016, Springer Science + Business Media

    Dr. Antonios Douros

  104. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study

    Article • International Journal of Molecular Sciences, January 2016, MDPI AG

    Dr. Antonios Douros

  105. Corrigendum

    Article • Expert Opinion on Drug Metabolism & Toxicology, October 2015, Taylor & Francis

    Dr. Antonios Douros

  106. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones

    Article • Expert Opinion on Drug Metabolism & Toxicology, October 2015, Informa Healthcare

    Dr. Antonios Douros

  107. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study

    Article • British Journal of Clinical Pharmacology, May 2015, Wiley

    Dr. Antonios Douros

  108. Estimating kidney function and use of oral antidiabetic drugs in elderly

    Article • Fundamental and Clinical Pharmacology, April 2015, Wiley

    Dr. Antonios Douros

  109. Erratum to: Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database

    Article • European Journal of Clinical Pharmacology, January 2015, Springer Science + Business Media

    Dr. Antonios Douros

  110. Safety issues and drug–drug interactions with commonly used quinolones

    Article • Expert Opinion on Drug Metabolism & Toxicology, November 2014, Informa Healthcare

    Dr. Antonios Douros

  111. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome

    Article • Thrombosis and Haemostasis, January 2014, Schattauer GmbH

    Dr. Antonios Douros

  112. Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database

    Article • European Journal of Clinical Pharmacology, December 2013, Springer Science + Business Media

    Dr. Antonios Douros

  113. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases

    Article • Alimentary Pharmacology & Therapeutics, August 2013, Wiley

    Dr. Antonios Douros

  114. Ramipril-Induced Liver Injury: Case Report and Review of the Literature

    Article • American Journal of Hypertension, June 2013, Oxford University Press (OUP)

    Dr. Antonios Douros